By gating on the CD11b+ population with gating strategies established previously (Supplementary Figure 2) (17, 30), we assessed the percentage of M-MDSC (CD11b+Ly6G−Ly6Chigh) vs. PMN-MDSC (CD11b+Ly6G+Ly6Clow) and the percentage of CD11b+Ly6C−Ly6G− population in both C-225 and C-100 tumors and in TB splenic controls (Figure 4C). This evidence concerns the gene ITGAM and tuberculosis.